Assignment:
Read "Ending HIV? Sangamo Therapeutics and Gene Editing" on pages 167-175.
Then, Answer the following questions:
1. What were the pros and cons of Sangamo Therapeutics, Inc. (Sangamo) pursuing its gene editing programs alone versus working with a partner?
2. What legal protections needed to be considered?
3. Does the HIV program offer any special opportunities or challenges?
4. What do you believe Sangamo should do regarding the HIV program?
a. Should it license the technology to a large pharmaceutical?
b. Should it form a joint venture with another biotech or pharma company? If so, who?
Length: 4 to 5 pages